2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2116

Neutrophil Extracellular Trap Formation Is Dependent on Disease Activity in Systemic Lupus Erythematosus: Determination Using a Flow Cytometry-Based Assay
Abstract Number: 2117

Neuropsychiatric Systemic Lupus Erythematosus Is Attenuated By Sphingosine-1-Phosphate Receptor Modulation
Abstract Number: 2118

Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Abstract Number: 2119

Association of the Variant Form of rs17408553 at Human Leukocyte Antigen-C Supports Evidence That Hypo-Responsive Natural Killer Cells Adversely Influence the Course of Nephritis
Abstract Number: 2120

CD47- Signal Regulatory Protein Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus
Abstract Number: 2121

Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney
Abstract Number: 2122

CD38 over-Expression in CD8 Positive Cells Defines a Group of Patients with SLE Prone to Infections
Abstract Number: 2123

Analysis of Lupus Synovitis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated within Infiltrating Immune Cells
Abstract Number: 2124

Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Abstract Number: 2125

Pleiotropy of a Positive Antinuclear Antibody (ANA) Test: A Phewas and GWAS Approach
Abstract Number: 2126

STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus
Abstract Number: 2127

A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis
Abstract Number: 2128

The Effect of miRNA-21 Overexpression on the Aberrant T Follicular Helper Cells Differentiation in Systemic Lupus Erythematosus
Abstract Number: 2129

Precipitating Anti-dsDNA Peptide Repertoires in Lupus
Abstract Number: 2130

Interferon Induced Gene Transcripts Are Differentially Upregulated in the Kidney of Lupus Nephritis Patients Irrespective of Activity or Damage

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].